Skip to main content
Fig. 1 | Trials

Fig. 1

From: Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Fig. 1

Time from submission of the protocol to the ethics committee and regulatory authority to completion of dosing of 8 SAD, 7 MAD, and 1 FE cohorts under standard industry timelines compared with what was achieved under accelerated conditions. SAD, single ascending dose; MAD, multiple ascending dose; FE, food effect; FIH, first in human

Back to article page